2009), while DURATION-6 showed substantial decreases in both HbA1c and weight with liraglutide relative to weekly exenatide (Drucker et al
This type of weight gain is known as sarcopenic obesity, which has adverse impacts on bodily functions, such as reduced muscular strength and mobility [4]
In conclusion, although GLP-1R expression was not found to be an independent prognostic factor in PDAC patients by immunohistochemical analysis, it appears to have some implications for PDAC metastatic ability
Thigh circumference and fat mass before and after the study
Combined Effects of GLP-1 Receptor Agonist and Exercise Training on Cardiorespiratory Fitness in Patients With Type 2 Diabetes: A Randomized Controlled Trial (NCT04122716)
She has been taking a GLP-1 drug, Zepbound, which she accessed through Ro, a direct-to-consumer telehealth company